title: The role of quinapril in the presence of a weight loss regimen: endothelial function and markers of obesity in patients with the metabolic syndrome.
abstract: Forty-four patients with the metabolic syndrome were placed on a reduced-calorie and reduced-fat regimen to lose weight throughout a 56-week period. The patients were treated in a crossover fashion with placebo and the angiotensin-converting enzyme inhibitor quinapril for 24 weeks each. The study measured endothelial-dependent flow-mediated dilation plus serum obesity markers of adiponectin and leptin. Metabolic parameters improved after 56 weeks. Serum adiponectin level increased by 18% (P<.05 vs baseline) and serum leptin level decreased by 16% with placebo (P<.05 vs baseline). These findings were potentiated further in the quinapril group. In comparison with baseline, flow-mediated dilation was increased by 13% in the placebo group (P=.055 vs baseline) and by 43% in the quinapril group (P<.001 vs baseline and placebo). These findings suggest that weight loss therapy improves endothelial function and markers of obesity. These results are potentiated with quinapril and are independent of changes in metabolic parameters.
authors.affiliation: Emory University School of Medicine, Division of Cardiology, Atlanta, GA 30303, USA.
authors.forename: Sameer
authors.initials: S
authors.lastname: Nagamia
authors.forename: Anbu
authors.initials: A
authors.lastname: Pandian
authors.forename: Faiz
authors.initials: F
authors.lastname: Cheema
authors.forename: Rama
authors.initials: R
authors.lastname: Natarajan
authors.forename: Qamar A
authors.initials: QA
authors.lastname: Khan
authors.forename: Amar D
authors.initials: AD
authors.lastname: Patel
authors.forename: Nadya
authors.initials: N
authors.lastname: Merchant
authors.forename: Srikanth
authors.initials: S
authors.lastname: Sola
authors.forename: Bobby V
authors.initials: BV
authors.lastname: Khan
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D004311:Double-Blind Method; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D020738:Leptin / Q000097:blood*; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000150:complications* / Q000503:physiopathology; D011379:Prognosis; D000077583:Quinapril; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use*; D014664:Vasodilation / Q000187:drug effects*; D015431:Weight Loss
chemical_list: D052242:Adiponectin; D000806:Angiotensin-Converting Enzyme Inhibitors; D015415:Biomarkers; D020738:Leptin; D044005:Tetrahydroisoquinolines; D000077583:Quinapril